What is NDC 0143-9166?

0143-9166 is the product NDC for Xtrenbo (denosumab-qbde), Denosumab 120 mg/1.7mL injection, listed with the FDA by Hikma Pharmaceuticals USA Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

Hikma Pharmaceuticals USA Inc., NDC labeler code 0143. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Xtrenbo?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Yes: J0897, Injection, denosumab, 1 mg.

Xtrenbo NDC 0143-9166 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)0143-9166Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00143-9166Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0143-9166-01	0014391660100143916601	1 VIAL, SINGLE-DOSE in 1 CARTON (0143-9166-01) / 1.7 mL in 1 VIAL, SINGLE-DOSEMarketed from Jan 8, 2026

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Xtrenbo
Generic name (nonproprietary): denosumab-qbde
Active ingredients: Denosumab — 120 mg/1.7mL
Dosage form: Injection
Route: Subcutaneous
Labeler: Hikma Pharmaceuticals USA Inc.NDC labeler code 0143
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 761439
Marketing start: Jan 8, 2026
Listing expires: Dec 31, 2027
Other FDA classes: RANK Ligand Blocking Activity (Mechanism)
Identifiers: Product ID 0143-9166_70159c7c-a439-4a9c-82d4-8c6da6c345ebSPL ID 70159c7c-a439-4a9c-82d4-8c6da6c345ebSPL set ID a48a3a33-6b0e-4cf4-8786-8f662d6ee77bRxCUI 2725590, 2725597UNII 4EQZ6YO2HI
Pharmacologic class: RANK Ligand Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeMed-Code curated

J0897 — Injection, denosumab, 1 mg

Billing unit: 1 mg. Units on the claim = dose given ÷ 1 mg.

Denosumab biosimilars have their own HCPCS codes.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N400143916601 followed by a unit qualifier and the quantity

Package 00143-9166-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Sep 2, 2025.

Indications (excerpt from the label)

Xtrenbo is a RANK ligand (RANKL) inhibitor indicated for: Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. ( 1.1 ) Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. ( 1.2 , 14.3 ) Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. ( 1.3 ) 1.1 Multiple Myeloma and Bone Metastasis from Solid Tumors Xtrenbo is indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. 1.2 Giant Cell…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 0143-9166

What is NDC 0143-9166?: 0143-9166 is the product NDC for Xtrenbo (denosumab-qbde), Denosumab 120 mg/1.7mL injection, listed with the FDA by Hikma Pharmaceuticals USA Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Xtrenbo (Denosumab-qbde).
What is the active ingredient?: Denosumab.
Who is the labeler?: Hikma Pharmaceuticals USA Inc., NDC labeler code 0143. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Xtrenbo?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Yes: J0897, Injection, denosumab, 1 mg. See Billing references above.

Other NDCs under BLA 761439

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under BLA 761439
Product	Strength	Form · route	Labeler	Product NDC
Enobydenosumab-qbde	Denosumab 60 mg/mL	InjectionSubcutaneous	Hikma Pharmaceuticals USA Inc.	0143-9165

Xtrenbo (Denosumab-qbde) NDC 0143-9166